

Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome

NCT06896708

Status	RECRUITING
Phase	Not Applicable
Sponsor	Liu yong
Enrollment	766 participants

Key Eligibility Criteria

Inclusion (2)

- \. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of e1.5mm that has not been intervened and at least one lesion with 50%-70% stenosis.
- \. Subjects who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C e1.8mmol/L or subjects who have not initiated lipid-lowering therapy prior to enrollment with a baseline LDL-Ce2.6mmol/L.

Exclusion (8)

- Left main coronary artery disease or severe three-vessel disease;
- Ultra-high-risk ASCVD patients: e2 severe ASCVD events or 1 severe ASCVD event with e2 high-risk factors;
- Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment;
- The baseline LDL-C was relatively high (LDL-Ce2.6 mmol/L in those taking statins and e4.9 mmol/L in those not taking statins).
- Familial hypercholesterolemia;
- ... and 3 more (see full listing online)

Locations (7 total)

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
The Ninth Clinical Medical College of Guangzhou University of Chinese Medicine, Dongguan, Guangdong, China
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
... and 4 more locations